Pipeline

Tackling a range of diseases with different approaches

We have established a portfolio of programs by selecting disease targets based on a number of criteria, including unmet medical need, technical feasibility, advantages of CRISPR/Cas9 relative to other approaches and time required to advance the product candidate into and through clinical trials.

Icon Hemo 80X80

Hemoglobinopathies

 
Research
Ind-Enabling
Clinical
Marketed
 
Icon Immuno 80X80

Immuno-Oncology

 
Research
Ind-Enabling
Clinical
Marketed
 
Icon Regen 80X80

Regenerative Medicine

 
Research
Ind-Enabling
Clinical
Marketed
 
Icon Invivo 80X80

In Vivo Approaches

 
Research
Ind-Enabling
Clinical
Marketed
 
 

Learn more about our programs and approaches

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.

Continue